Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.

Xu Y, Jin L, Liu N, Luo X, Dong D, Tang J, Wang Y, You Y, Liu Y, Chen M, Yu Z, Hao Y, Gu Q.

Int J Infect Dis. 2019 Mar 13;82:79-85. doi: 10.1016/j.ijid.2019.03.011. [Epub ahead of print]

2.
3.

In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.

Schentag JJ, Birmingham MC, Paladino JA, Carr JR, Hyatt JM, Forrest A, Zimmer GS, Adelman MH, Cumbo TJ.

Semin Respir Infect. 1997 Dec;12(4):278-93. Review.

PMID:
9436955
4.

Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

McKinnon PS, Paladino JA, Schentag JJ.

Int J Antimicrob Agents. 2008 Apr;31(4):345-51. doi: 10.1016/j.ijantimicag.2007.12.009. Epub 2008 Mar 4.

PMID:
18313273
6.

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ.

Antimicrob Agents Chemother. 1993 May;37(5):1073-81.

7.

Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy.

Highet VS, Forrest A, Ballow CH, Schentag JJ.

J Antimicrob Chemother. 1999 Mar;43 Suppl A:55-63.

PMID:
10225573
8.
9.
10.
11.

High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.

De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, Spanu T, Tumbarello M, Antonelli M.

Crit Care. 2014 May 5;18(3):R90. doi: 10.1186/cc13858.

12.

Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria.

Zaidi ST, Al Omran S, Al Aithan AS, Al Sultan M.

J Clin Pharm Ther. 2014 Jun;39(3):272-6. doi: 10.1111/jcpt.12138. Epub 2014 Mar 5.

PMID:
24593154
13.
14.

Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens.

Chen Z, Shi X.

Medicine (Baltimore). 2018 Sep;97(38):e12467. doi: 10.1097/MD.0000000000012467.

15.

Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients.

Ruiz J, Ramirez P, Company MJ, Gordon M, Villarreal E, Concha P, Aroca M, Frasquet J, Remedios-Marqués M, Castellanos-Ortega Á.

J Glob Antimicrob Resist. 2018 Mar;12:90-95. doi: 10.1016/j.jgar.2017.09.019. Epub 2017 Oct 7.

PMID:
29017888
16.

Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.

Bland CM, Pai MP, Lodise TP.

Pharmacotherapy. 2018 Dec;38(12):1229-1238. doi: 10.1002/phar.2193.

PMID:
30403305
17.
18.

Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.

Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M.

Chest. 2010 Dec;138(6):1333-9. doi: 10.1378/chest.10-0463. Epub 2010 Jun 17.

PMID:
20558557
19.
20.

Supplemental Content

Support Center